archTIS Limited ((ASX: AR9) has announced a second U.S. Department of Defense–related contract, this time to deliver customised development work on its NC Protect product for the Microsoft DoD365 environment via federal contractor Copper River Technologies. While modest in dollar terms, management frames this engagement as a bridge that advances enterprise-grade rollout and positions the company for a larger licensing outcome already flagged earlier in the year.

Proteomics International (ASX: PIQ) has expanded its research agreement with the University of Melbourne and the Royal Women’s Hospital (RWH), a leading centre for endometriosis research. The partnership has two clear streams: (1) additional clinical validation for Promarker®Endo—PIQ’s first-in-class blood test for diagnosing endometriosis—and (2) discovery work toward a tissue-specific, next-generation test using peritoneal fluid to improve disease localisation.

Medibank Private has expanded its multi-year funding agreement with Emyria Limited (ASX: EMD) to support screened and eligible customers accessing Empax programs for Treatment-Resistant Depression (TRD) and Post-Traumatic Stress Disorder (PTSD) at Avive Clinic Brisbane (Figure 1). Clinic fit-out and regulatory preparations are underway, with treatment commencement targeted for Q4 CY2025. This marks Emyria’s first insurer-backed program on Australia’s east coast and advances t

Xstate Resources Limited (ASX: XST) has provided an operations update for Diona-1 within the Diona block, ATP 2077, in the Surat–Bowen Basin, Queensland (Figure 1). As at the time of writing, the well had reached 2,479 m MD, intersected its Jurassic primary target (non-hydrocarbon-bearing), and on entering the Permian encountered an ~181 m hydrocarbon-prone sequence with a significant overpressured gas column.

Encounter Resources Limited (ASX: ENR)’s latest Aileron results sharpen the focus on Green Prospect (Figure 1) as the emerging high-grade core of this West Arunta carbonatite system. A standout 85m @ 3.1% Nb₂O₅ within a thicker 124m envelope materially upgrades grade continuity inside—and beyond—the current resource shell.

Algorae Pharmaceuticals Ltd (ASX: 1AI) has executed a binding term sheet with Cadila Pharmaceuticals Limited for a proposed license and supply agreement covering Australia and New Zealand. The partnership would see Algorae launch two generic medicines targeting cardiovascular and metabolic disorders, with next steps focused on finalising a definitive agreement and preparing for TGA registration.

E79 Gold Limited (ASX: E79) has sharpened the Mountain Home Copper–Gold (Figure 1) story in the NT with a simple but telling update (23 October 2025): fresh mapping plus 24 rock-chip samples have pushed high-grade copper outside the known gossan and onto parallel trends. With assays up to 35.9% Cu and Cu-Au-Bi mineralisation tracking along sinistral brittle faults, the footprint now looks more like a structural corridor than a single showing.

Lion Rock Minerals Limited (ASX: LRM) has secured a strategic placement and technical partnership with Tronox Holdings plc (NYSE: TROX)—one of the world’s largest vertically-integrated titanium dioxide and zircon producers. This is not just funding; it’s an alignment with an operator that mines, upgrades, and markets titanium feedstocks (including rutile) and rare earth-bearing monazite at industrial scale. The move signals an intention to fast-track drilling, resource defini

TrivarX Limited (ASX: TRI) announced a binding option to acquire Stabl-Im™, a stable-isotope MRI platform intended to enable early, repeatable, non-invasive detection and monitoring of brain tumours and metastases—an area with high unmet clinical need and limited safe imaging options. The transaction is paired with a $4.2m placement cornerstoned by Dr Daniel Tillett (founder/CEO of Nucleics and MD/CEO of Race Oncology, ASX: RAC), signalling both technical belief and strategic

Latrobe Magnesium (ASX: LMG) is progressing an Australian-first pathway to produce magnesium and associated by-products from brown coal ash via a patented hydromet/thermal reduction process (Figure). In late September 2025, LMG confirmed first production of magnesium oxide (MgO) from its Hazelwood North Demonstration Plant—an operational milestone that further de-risks the flowsheet ahead of magnesium metal commissioning.